Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics IncfiledCriticalAmicus Therapeutics Inc
Publication of AR114938A1publicationCriticalpatent/AR114938A1/en
Variantes de la enzima CDKL5, y proteínas de fusión que comprenden polipéptidos CDKL5 de longitud completa o variantes de CDKL5. Dichas proteínas de fusión pueden incluir polipéptidos penetradores de células y opcionalmente comprenden polipéptidos de señales directrices y/o marcas. También se proveen métodos para producir dichas variantes y proteínas de fusión CDKL5, así como composiciones farmacéuticas, métodos de tratamiento y usos de dichas proteínas recombinantes.Variants of the CDKL5 enzyme, and fusion proteins comprising full-length CDKL5 polypeptides or CDKL5 variants. Such fusion proteins can include cell-penetrating polypeptides and optionally comprise leader and / or tag polypeptides. Methods for producing said CDKL5 fusion proteins and variants are also provided, as well as pharmaceutical compositions, treatment methods and uses of said recombinant proteins.
ARP180103526A2017-11-302018-12-03
EXPRESSION VARIANTS OF CDKL5 AND FUSION PROTEINS CDKL5
AR114938A1
(en)
Method for producing oxalate oxidases having optical activity near physiological pH and use of such recombinant oxalate oxidases in the treatment of oxalate-related diseases